Healthy Volunteers
Conditions
Brief summary
Phase one study to evaluate the safety and dosimetry of \[68Ga\]-NOTA-hGZP (CSB-111) PET Imaging in healthy human volunteers.
Detailed description
This study aims to assess the safety and evaluate the dosimetry of CSB-111. This study will estimate organ dosimetry and the overall effective dose, a requirement for expanding the human use of a radiopharmaceutical.
Interventions
DRUGCSB-111
\[68Ga\]-NOTA-hGZP is a PET imaging agent.
Sponsors
University of Alabama at Birmingham
Cytosite Biopharma Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female healthy participants aged between 18 and 65 years old. 2. For females of childbearing potential, a negative serum or urine beta-human chorionic gonadotropin (β-hCG) pregnancy test must be obtained at the day of the procedure prior to CSB-111 administration. 3. Willing and able to undergo all study procedures. 4. Willing and able to understand the written informed consent and sign the consent document prior to any study-related procedure. 5. Willing to refrain from strenuous exercise for the 24 hours prior to CSB-111 administration
Exclusion criteria
1. History of allergic reactions to compounds of similar chemical or biologic composition to CSB-111. 2. Prior malignancy except for fully resected skin cancers. 3. Current treatment with systemic steroids, or immunosuppressive agents. 4. Known renal or hepatic disease. 5. Laboratory values: 1. Leukocytes \<3000/mcL 2. Absolute neutrophil count \<1500 mcL 3. Platelets \<100,000 mcL 4. Total bilirubin \>1.5 x Upper limit of normal (ULN) 5. Aspartate Transaminase (AST)/ Alanine Aminotransferase (ALT) \>2.5 x ULN 6. Albumin \<3.7 g/dL 7. Gamma glutamyl transferase (GGT) \>2.5 ULN 8. eGFR \<60 mL/min/1.73 m2 measured in the prior 30 days before administration of CSB-111 6. Having received any investigational product in the prior three months of receiving CSB-111. 7. Currently participating in any clinical trials, except observational studies. 8. Any acute or chronic inflammatory disease, autoimmune disorders, or medical conditions that in the investigator's opinion may interfere with the study procedures or the interpretation of the study results such as infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia. 9. Participants who have any condition that would prevent them from receiving a PET scan. 10. Female participants who are pregnant (confirmed via a positive serum or urine β-hCG test on the day of procedure prior to CSB-111 administration). 11. Female participants who are breastfeeding. 12. Unable or unwilling to use adequate contraception prior to study, during study participation and for one week post-injection for both females and males. 13. Any medical condition which, in the opinion of the investigator, may interfere with participation in the study and/or alter the biodistribution of CSB-111. 14. Mentally incapacitated or unable to understand the informed consent. 15. Participants who, in the opinion of the investigator, have underlying psychological conditions which may negatively impact their wellbeing if participating. 16. Prisoners. 17. Staff and family members of CytoSite. 18. Staff reporting to the principal investigator (PI).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of intact CSB-111 in blood samples up to 185 min after injection, using HPLC | From 65 to 185 minutes after injection | Intact CSB-111 percentage in blood |
| Concentration of intact CSB-111 in urine | up to 4 hours after injection or until below the level of detection | Intact CSB-111 in urine in picograms |
| Percentage of intact CSB-111 in urine | up to 4 hours after injection or until below the level of detection | Percentage of intact CSB-111 in urine compared to initial dose |
| Organ-level dosimetry of CSB-111 and total body and effective dose | PET/CT imaging up to 180 minutes post-injection | milli-Sieverts \[mSi\] |
| Total radioactivity via gamma counter of cell pellet, plasma protein and unbound radioactivity in blood samples up to 65 min | Up to to 185 minutes post dose | milli-Curies \[mCi\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall AEs frequency and frequency per grade of AEs related to CSB-111 according to Medical Dictionary for Regulatory Activities (MedDRA)/ Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0 | up to 2 days post dose | Overall AEs frequency and frequency per grade of AEs. All AE's in this study will be listed as an endpoint. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Regional (organ) accumulation of CSB-111 | PET/CT imaging up to 180 minutes post-injection or until below limits of detection | Dosimetry in organs in milli-Sieverts \[mSi\] |
Countries
United States
Outcome results
None listed